Exchange: NASDAQ·Updated 03:28 PM EDT
Latest Earnings Results: Q2 '26

Reported: Aug 04

Estimated EPS

-$1.22

Reported EPS

-$0.90

Surprise

+26.09%

Estimated Rev

$183.08M

Reported Rev

$214M

Surprise

+16.89%

$RARE Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.90 up 23.08% YoY • Reported revenue of $214M up 28.53% YoY • Ultragenyx Pharmaceutical Inc. reaffirms its 2026 full-year total revenue guidance of $730 million to $760 million, excluding potential new product launches, while remaining on track toward profitability in 2027.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.93
--
--
N/A
Q2 '26
-$1.22
-$0.90
26.09%
BEAT
Q1 '26
-$1.50
-$1.84
-22.93%
MISSED
Q4 '25
-$1.09
-$1.29
-18.07%
MISSED
Q3 '25
-$1.23
-$1.81
-46.69%
MISSED

Advertisement|Remove ads.